Cochrane · systematic review · CD008536
Short‐term and long‐term effects of tibolone in postmenopausal women
Formoso, G, Perrone, E, Maltoni, S, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
16
current version
GRADE rated
16
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 11 · 68.8%Low 1 · 6.3%Moderate 4 · 25%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyTibolone compared with placebo for treatment of vasomotor symptoms in postmenopausal women
Population: postmenopausal women with vasomotor symptoms
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Vasomotor symptoms (all doses) Tibolone vs placebo | OR 0.33 [0.27, 0.41] | 5 studies · 842 participants | Moderate Downgraded: risk of bias |
Tibolone compared with placebo for postmenopausal women: adverse events
Population: postmenopausal women with or without vasomotor symptoms
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Endometrial cancer (all doses) Tibolone vs placebo | OR 2.04 [0.79, 5.24] | 9 studies · 8504 participants | Very low Downgraded: risk of bias |
Breast cancer; women without previous breast cancer (all doses) Tibolone vs placebo | OR 0.52 [0.21, 1.25] | 4 studies · 5500 participants | Very low Downgraded: risk of bias |
Unscheduled bleeding (all doses) Tibolone vs placebo | OR 2.79 [2.1, 3.7] | 9 studies · 7814 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |
Venous thromboembolic events (clinical evaluation) all doses Tibolone vs placebo | OR 0.85 [0.37, 1.97] | 5 studies · 9176 participants | Very low Downgraded: risk of bias |
Cardiovascular events (all doses) Tibolone vs placebo | no estimate extracted | 4 studies · 8401 participants | Very low Downgraded: risk of bias |
Cerebrovascular events (all doses) Tibolone vs placebo | OR 1.74 [0.99, 3.04] | 4 studies · 7930 participants | Very low Downgraded: risk of bias |
Mortality from any cause (all doses) Tibolone vs placebo | OR 1.06 [0.79, 1.41] | 4 studies · 8242 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Tibolone compared with combined HT for treatment of vasomotor symptoms in postmenopausal women
Population: postmenopausal women with vasomotor symptoms
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Vasomotor symptoms (tibolone 2.5 mg/d) Tibolone vs combined HT | OR 1.57 [1.18, 2.1] | 4 studies · 646 participants | Moderate Downgraded: risk of bias |
Tibolone compared with combined HT for postmenopausal women: adverse events
Population: postmenopausal women with or without vasomotor symptoms
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Unscheduled bleeding (all doses) Tibolone vs combined HT | OR 0.32 [0.24, 0.41] | 16 studies · 6438 participants | Moderate Downgraded: risk of bias |
Endometrial cancer (all doses) Tibolone vs combined HT | OR 1.47 [0.23, 9.33] | 5 studies · 3689 participants | Very low Downgraded: risk of bias, imprecision |
Breast cancer; women without previous breast cancer (all doses) Tibolone vs combined HT | OR 1.69 [0.78, 3.67] | 5 studies · 4835 participants | Very low Downgraded: risk of bias, imprecision |
Venous thromboembolic events (clinical evaluation; all doses) Tibolone vs combined HT | OR 0.44 [0.09, 2.14] | 4 studies · 4529 participants | Very low Downgraded: risk of bias, imprecision |
Cardiovascular events (all doses) Tibolone vs combined HT | OR 0.63 [0.24, 1.66] | 2 studies · 3794 participants | Very low Downgraded: risk of bias, imprecision |
Cerebrovascular event (all doses) Tibolone vs combined HT | OR 0.76 [0.16, 3.66] | 4 studies · 4562 participants | Very low Downgraded: risk of bias, imprecision |
Mortality from any cause (tibolone 2.5 mg/d) Tibolone vs combined HT | OR 3.05 [0.12, 75.2] | 2 studies · 970 participants | Very low Downgraded: risk of bias, imprecision |
Unscheduled bleeding (tibolone versus placebo)
Population: women in menopause
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Unscheduled bleeding (all studies) Unscheduled bleeding (tibolone vs placebo) | OR 2.75 [1.99, 3.8] | 7 studies · 7462 participants | Very low |
Unscheduled bleeding (tibolone 2.5 mg) Unscheduled bleeding (tibolone vs placebo) | OR 2.51 [1.71, 3.67] | 6 studies · 3834 participants | Very low |
Unscheduled bleeding (tibolone 1.25 mg) Unscheduled bleeding (tibolone vs placebo) | OR 3.63 [2.37, 5.55] | 3 studies · 3628 participants | Very low |
Unscheduled bleeding (tibolone versus combined HT)
Population: women in menopause
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Unscheduled bleeding (all studies) Unscheduled bleeding (tibolone vs combined HT) | OR 0.32 [0.24, 0.42] | 15 studies · 6342 participants | Very low |
Unscheduled bleeding (tibolone 2.5 mg) Unscheduled bleeding (tibolone vs combined HT) | OR 0.35 [0.26, 0.46] | 15 studies · 4624 participants | Low |
Unscheduled bleeding (tibolone 1.25 mg) Unscheduled bleeding (tibolone vs combined HT) | OR 0.21 [0.16, 0.26] | 2 studies · 1718 participants | Moderate |